Chiron Beats Street Estimates

Biotech/Pharmaceuticals

Adam Feuerstein

04/25/01 - 04:30 PM EDT

Chiron(CHIR Quote) posted a first-quarter profit of $38 million, or 19 cents per share, minus special items, which beat Wall Street consensus estimates by 2 cents.

First quarter earnings did fall below last year's results of $40 million, or 21 cents per share.

The Emeryville, Calif. biopharmaceutical firm said total pro-forma first quarter revenue rose 11% to $240 million, compared to $217 million in the year-ago quarter.

The company also reiterated an earlier forecast for pro-forma earnings of 85 cents per share in 2001, which is a penny below Wall Street consensus, according to Multex.com.

Chiron shares closed up 97 cents, or 2.3%, to $43.79 in Wednesday trading.

Visit TheStreet for more great features

TheStreet Premium Services

From the action-oriented investing ideas of Action Alerts PLUS by Jim Cramer to the expert technical trading strategies of Helene Meisler's Top Stocks, TheStreet.com offers a range of premium services to help boost your portfolio's performance. View now.

Expert Advisors Alerts Delivered to your Inbox

Action Alerts PLUS: Cramer's personal portfolio, emails before he acts.

RealMoney: 70+ experts share their top investing ideas and analysis.

Stocks Under $10: Alerts identify undervalued stocks with profit potential.

FREE NEWSLETTERS

Get an edge on the market with the help of free email newsletters like Jim Cramer's Daily Booyah!. Learn about the day's major market events, companies that sizzled or fizzled and lots more that can help you make more profitable investing decisions. Sign up.